ReviewBMC nephrology2025
Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Sarcopenia Definitions and Diagnostic Challenges Across Diverse Clinical Populations: A Scoping Review.Health science reports · 2026Article
- Using a generative co-design framework to adapt an exercise intervention as part of a multimodal intervention for patients' receiving haemodialysis with or at risk of renal cachexia.Research involvement and engagement · 2026Article
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
- Gut microbiota-derived metabolites as immune modulators in aging and age-related chronic inflammatory diseases.Ageing research reviews · 2026Review
- Nutritional and Metabolic Interventions to Prevent and Treat Protein-Energy Wasting in Nondialysis CKD-Narrative Review.Nutrients · 2026Review
- Prognostic value of the triglyceride-glucose (TyG) index for renal function progression in patients with CKD stages 3-4.Frontiers in nutrition · 2026Article
- Neuromuscular Electrical Stimulation During Hemodialysis Enhances Exercise Capacity in Patients with End-Stage Renal Disease: A Pilot Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- Multi-Omics Alterations in Rat Kidneys upon Chronic Glyphosate Exposure.Biomolecules · 2025Article
- When the Heart, Kidneys, and Body Waste Away: A Review of Cachexia in Cardiorenal Syndrome.Current heart failure reports · 2025Review
- Carnitine Deficiency in Chronic Kidney Disease: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Nutrients · 2025Review
- Malnutrition in Elderly Patients with Chronic Kidney Disease-The Role of Albuminuria.Life (Basel, Switzerland) · 2025Article
- Perinatal Vitamin D Deficiency Enhances Brown Adipose Tissue Thermogenesis in Weanling Rats.International journal of molecular sciences · 2025Article
- Investigating the association of bioelectrical impedance analysis-derived phase angle and depressive symptoms in patients receiving maintenance hemodialysis: a cross-sectional study.Frontiers in nutrition · 2025Article
- Association between serum bicarbonate levels and 28-day in-hospital mortality in dialysis patients: a multicenter retrospective cohort study based on the eICU Collaborative Research Database.Frontiers in medicine · 2025Article
- The gut-muscle axis: a comprehensive review of the interplay between physical activity and gut microbiota in the prevention and treatment of muscle wasting disorders.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2008, the Society on Sarcopenia, Cachexia, and Wasting Disorders introduced a generic definition for all types of cachexia: "a complex metabolic syndrome associated with the underlying illness characterized by a loss of muscle, with or without fat loss". It is well-known that the presence of inflammatory burden in end-stage renal disease (ESRD) patients may lead to the evolution of cachexia. Since the etiology of cachexia in chronic kidney disease (CKD) is multifactorial, thus the successful treatment must involve several concomitant measures (nutritional interventions, appetite stimulants, and anti-inflammatory pharmacologic agents) to provide integrated effective therapeutic modalities to combat causative factors and alleviate the outcomes of patients. Given the high mortality rate associated with cachexia, developing new therapeutic modalities are prerequisite for ameliorating patients with CKD worldwide. The present review aims to discuss some therapeutic strategies and provide an update on advances in nutritional approaches to counteract cachexia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.